



# Updates from the 6th PPR Vaccine Producers Meeting

Dr Duriya Charypkhan
PPR Secretariat







# The sixth PPR vaccine producers meeting







### **Context and Purpose**

Previous meetings in Nepal (2014), Morocco (2017), Jordan (2019), virtually (2021), and India (2023)

- Supported by Dollvet, brought together producers from Africa, the Middle East, Asia, and Europe
- Reviewed progress since 2023 meeting in India
- Discussed vaccine quality, production capacity, thermotolerant and DIVA vaccines

## **Main discussion points**

- Some government producers are seeking help in securing vaccine seeds from reference labs
- Requesting also DIVA strains
- Support in QC needed
- Production capacity exceeds the current demands

#### **Research and Innovation**

- Rapid advances in thermotolerant and DIVA vaccine R&D
- MCI: Developing combined and DIVA vaccines
- JOVAC: Up-scaling Nig 75/1 DIVA strain safe at 10× dose
- Promote technology transfer and knowledge sharing within GREN



- Conventional vaccines limit sero-surveillance differentiation
- DIVA vaccines allow vaccination without losing free status
- Enable safe trade and regional control
- Align with WOAH Resolution No. 29 promoting new vaccine platforms

#### **Global momentum**

- WOAH developing Target Product Profiles (TPPs) for priority diseases
- Promotes new biotech platforms (mRNA, viral vectors)
- Ensures trade recognition of vaccinated animals
- Supports consensus inclusion of DIVA vaccines in standards



# **PPR incursions toward Europe** heighten urgency DIVA vaccines enable:

- Pre-emptive vaccination in at-risk zones
- "Free with vaccination" status (FMD-like model)
- Safe trade and new markets
- Growth in diagnostics and high-value vaccines

#### **Main recommendations**

- Finalize PPR DIVA Target Product Profile (TPP)
- Integrate DIVA vaccines & diagnostics into WOAH Manual & Code
- Conduct national risk analyses for DIVA/TT use
- Strengthen public—private partnerships
- Mobilize funding for R&D and field testing



- 7th PPR Vaccine Producers Meeting: April 2027, Morocco (Biopharma)
- Producers to report DIVA/TT vaccine progress
- Continued coordination with FAO-WOAH Secretariat and AU-PANVAC